Skip to main content
SpringerLink
Log in

Angiotensin-Converting Enzyme Inhibitors

  • Chapter
  • First Online:
Adverse Cutaneous Drug Reactions to Cardiovascular Drugs

  • 949 Accesses

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) can be classified into two sub groups according to their chemical structure: the one containing a thiol (or sulfhydryl [SH]) group such as captopril and zofenopril, and the other lacking a thiol group such as enalapril, ramipril, cilazapril, fosinopril, quinapril, trandolapril, lisinopril, perindopril, moexipril, benazepril, imidapril, delapril, alecepril, and spirapril.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Steckelings UM, Artuc M, Wollschlager T, Wiehstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol. 2001;81:321–5.

    CAS  PubMed  Google Scholar 

  2. Kyrmizakis DE, Papadakis CE, Liolios AD, Karatzanis AD, Malandrakis S, Skoulakis CE, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg. 2004;130:1416–9.

    PubMed  Google Scholar 

  3. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica. 1990;181:51–3.

    CAS  PubMed  Google Scholar 

  4. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol. 1980;116:902–5.

    CAS  PubMed  Google Scholar 

  5. Winters ME, Rosenbaum S, Vilke GM, Almazroua FY. Emergency department management of patients with ACE-inhibitor angioedema. J Emerg Med. 2013;45:775–80.

    PubMed  Google Scholar 

  6. Rasmussen ER, Mey K, Bygum A. Angiotensin-converting Enzyme Inhibitor-induced Angioedema – A Dangerous New Epidemic. Acta Derm Venereol. 2014;94:260–4. doi:10.2340/00015555-1760.

    PubMed  Google Scholar 

  7. Cohen EG, Soliman AM. Changing trends in angioedema. Ann Otol Rhinol Laryngol. 2001;110:701–6.

    CAS  PubMed  Google Scholar 

  8. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, Levy E. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637–42.

    CAS  PubMed  Google Scholar 

  9. Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, et al. Pollen count and presentation of Angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol Pract. 2013;1:468–73.

    PubMed Central  PubMed  Google Scholar 

  10. Pillans PI, Coulter DM, Black P. Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol. 1996;51:123–6.

    CAS  PubMed  Google Scholar 

  11. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andren L, Wiholm BE. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992;304:941–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Chalmers D, Whitehead A, Lawson DH. Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol. 1992;34:215–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Lee A, Thomson J. Drug-induced skin reactions. In: Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006. p. 125–56.

    Google Scholar 

  14. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18:171–88.

    CAS  PubMed  Google Scholar 

  15. Chu TJ, Chow N. Adverse effects of ACE inhibitors. Ann Intern Med. 1993;118:314.

    CAS  PubMed  Google Scholar 

  16. Garcia-Pavia P, Tomas JM, Alonso-Pulpón L. Late-onset angioedema due to an angiotensin-converting enzyme inhibitor. Can J Cardiol. 2007;23:315–6.

    PubMed Central  PubMed  Google Scholar 

  17. Norman JL, Holmes WL, Bell WA, Finks SW. Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril. J Pharm Pract. 2013;26:382–8.

    PubMed  Google Scholar 

  18. Amey G, Waidyasekara P, Kollengode R. Delayed presentation of ACE inhibitor-induced angio-oedema. BMJ Case Rep. 2013;2013. doi: 10.1136/bcr-2013-010453.

  19. Howarth D. ACE inhibitor angioedema – a very late presentation. Aust Fam Physician. 2013;42:860–2.

    PubMed  Google Scholar 

  20. Lewis LM. Angioedema: etiology, pathophysiology, current and emerging therapies. J Emerg Med. 2013;45:789–96.

    PubMed  Google Scholar 

  21. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495–9.

    PubMed  Google Scholar 

  22. Wolf R, Tamir A, Brenner S. Drug-induced versus drug-triggered pemphigus. Dermatologica. 1991;182:207–10.

    CAS  PubMed  Google Scholar 

  23. Ong CS, Cook N, Lee S. Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol. 2000;41:242–6.

    CAS  PubMed  Google Scholar 

  24. Baričević M, Mravak Stipetić M, Situm M, Marinović B, Seiwerth S, Baričević D, et al. Oral bullous eruption after taking lisinopril–case report and literature review. Wien Klin Wochenschr. 2013;125:408–11. doi:10.1007/s00508-013-0382-7.

    PubMed  Google Scholar 

  25. Al-Niaimi F. Drug eruptions in dermatology. Expert Rev Dermatol. 2011;6:273–86.

    Google Scholar 

  26. Ruocco V, de Angelis E, Lombardi ML, Pisani M. In vitro acantholysis by captopril and thiopronine. Dermatologica. 1988;176:115–23.

    CAS  PubMed  Google Scholar 

  27. Butt A, Burge SM. Pemphigus vulgaris induced by captopril. Br J Dermatol. 1995;132:315–6.

    CAS  PubMed  Google Scholar 

  28. Thami GP, Kaur S, Kanwar AJ. Severe childhood pemphigus vulgaris aggravated by enalapril. Dermatology. 2001;202:341.

    CAS  PubMed  Google Scholar 

  29. Parodi A, Cozzani E, Milesi G, Drosera M, Rebora A. Fosinopril as a possible pemphigus-inducing drug. Dermatology. 2002;204:139–41.

    CAS  PubMed  Google Scholar 

  30. Shelton RM. Pemphigus foliaceus associated with enalapril. J Am Acad Dermatol. 1991;24:503–4.

    CAS  PubMed  Google Scholar 

  31. Vignes S, Paul C, Flageul B, Dubertret L. Ramipril-induced superficial pemphigus. Br J Dermatol. 1996;135:657–8.

    CAS  PubMed  Google Scholar 

  32. Buzon E, Perez-Bernal AM, de la Pena F, Rios JJ, Camacho F. Pemphigus foliaceus associated with cilazapril. Acta Derm Venereol. 1998;78:227.

    CAS  PubMed  Google Scholar 

  33. Patterson CR, Davies MG. Pemphigus foliaceus: an adverse reaction to lisinopril. J Dermatolog Treat. 2004;15:60–2.

    CAS  PubMed  Google Scholar 

  34. Pinto GM, Lamarao P, Vale T. Captopril-induced pemphigus vegetans with Charcot-Leyden crystals. J Am Acad Dermatol. 1992;27:281–4.

    CAS  PubMed  Google Scholar 

  35. Bastiaens MT, Zwan NV, Verschueren GL, Stoof TJ, Nieboer C. Three cases of pemphigus vegetans: induction by enalapril–association with internal malignancy. Int J Dermatol. 1994;33:168–71.

    CAS  PubMed  Google Scholar 

  36. Adriano AR, Gomes Neto A, Hamester GR, Nunes DH, Di Giunta G. Pemphigus vegetans induced by use of enalapril. An Bras Dermatol. 2011;86:1197–200.

    PubMed  Google Scholar 

  37. Ruocco V, Satriano RA, Guerrera V. “Two-step” pemphigus induction by ACE-inhibitors. Int J Dermatol. 1992;31:33–6.

    CAS  PubMed  Google Scholar 

  38. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol. 1992;26:364–6.

    CAS  PubMed  Google Scholar 

  39. Femiano F, Scully C, Gombos F. Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:169–73.

    PubMed  Google Scholar 

  40. Friedman IS, Rudikoff D, Phelps RG, Sapadin AN. Captopril-triggered linear IgA bullous dermatosis. Int J Dermatol. 1998;37:608–12.

    CAS  PubMed  Google Scholar 

  41. Flageul B, Foldes C, Wallach D, Vignon-Pennamen MD, Cottenot F. Captopril-induced lichen planus pemphigoides with pemphigus-like features. A case report. Dermatologica. 1986;173:248–55.

    CAS  PubMed  Google Scholar 

  42. Ben Salem C, Chenguel L, Ghariani N, Denguezli M, Hmouda H, Bouraoui K. Captopril-induced lichen planus pemphigoides. Pharmacoepidemiol Drug Saf. 2008;17:722–4.

    CAS  PubMed  Google Scholar 

  43. Ogg GS, Bhogal BS, Hashimoto T, Coleman R, Barker JN. Ramipril-associated lichen planus pemphigoides. Br J Dermatol. 1997;136:412–4.

    CAS  PubMed  Google Scholar 

  44. Zhu YI, Fitzpatrick JE, Kornfeld BW. Lichen planus pemphigoides associated with ramipril. Int J Dermatol. 2006;45:1453–5.

    PubMed  Google Scholar 

  45. Mallet L, Cooper JW, Thomas J. Bullous pemphigoid associated with captopril. DICP. 1989;23:63.

    CAS  PubMed  Google Scholar 

  46. Fitzgerald DA. Subepidermal bullous eruption induced by captopril. Clin Exp Dermatol. 1993;18:196–7.

    CAS  PubMed  Google Scholar 

  47. Smith EP, Taylor TB, Meyer LJ, Zone JJ. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol. 1993;29(5 Pt 2):879–82.

    CAS  PubMed  Google Scholar 

  48. Kalińska-Bienias A, Rogoziński TT, Woźniak K, Kowalewski C. Can pemphigoid be provoked by lisinopril? Br J Dermatol. 2006;155:854–5.

    PubMed  Google Scholar 

  49. Wong SS, Long CC, Holt PJ. Lichenoid eruption induced by low dose captopril. Acta Derm Venereol. 1992;72:358–9.

    CAS  PubMed  Google Scholar 

  50. Revenga Arranz F, Gonzalo Garijo MA. Lichenioid reaction induced by captopril. Rev Clin Esp. 1996;196:412.

    CAS  PubMed  Google Scholar 

  51. Cox NH, Tapson JS, Farr PM. Lichen planus associated with captopril: a further disorder demonstrating the ‘tin-tack’ sign. Br J Dermatol. 1989;120:319–21.

    CAS  PubMed  Google Scholar 

  52. Rotstein E, Rotstein H. Drug eruptions with lichenoid histology produced by captopril. Australas J Dermatol. 1989;30:9–14.

    CAS  PubMed  Google Scholar 

  53. Reinhardt LA, Wilkin JK, Kirkendall WM. Lichenoid eruption produced by captopril. Cutis. 1983;31:98–9.

    CAS  PubMed  Google Scholar 

  54. Bravard P, Barbet M, Eich D, Weber M, Daniel F, Lauret P. Captopril induced lichenoid eruption. Ann Dermatol Venereol. 1983;110:433–8.

    CAS  PubMed  Google Scholar 

  55. Wolf R, Tamir A, Srebrnik A, Brenner S. Lichenoid eruption and alopecia associated with captopril treatment. J Dermatolog Treat. 1990;1:155–7.

    Google Scholar 

  56. Ruiz Villaverde R, Blasco Melguizo J, Linares Solano J, Serrano Ortega S. Lichen planus-like eruption due to enalapril. J Eur Acad Dermatol Venereol. 2003;17:612–4.

    CAS  PubMed  Google Scholar 

  57. Roten SV, Mainetti C, Donath R, Saurat JH. Enalapril-induced lichen planus-like eruption. J Am Acad Dermatol. 1995;32:293–5.

    CAS  PubMed  Google Scholar 

  58. Kanwar AJ, Dhar S, Ghosh S. Photosensitive lichenoid eruption due to enalapril. Dermatology. 1993;187:80.

    CAS  PubMed  Google Scholar 

  59. Shackelton JB, English 3rd JC. Acute-onset reticulated white lip. JAMA. 2011;306:2267–8.

    CAS  PubMed  Google Scholar 

  60. Furness PN, Goodfield MJ, MacLennan KA, Stevens A, Millard LG. Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides. J Clin Pathol. 1986;39:902–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Mutasim DF. Lymphomatoid drug eruption mimicking digitate dermatosis: cross reactivity between two drugs that suppress angiotensin II function. Am J Dermatopathol. 2003;25:331–4.

    PubMed  Google Scholar 

  62. Carroll J, Thaler M, Grossman E, Alder A, Trau H, Rosenthal T. Generalized pustular eruption associated with converting enzyme inhibitor therapy. Cutis. 1995;56:276–8.

    CAS  PubMed  Google Scholar 

  63. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis. 1987;40:162–4.

    CAS  PubMed  Google Scholar 

  64. Coulter DM, Pillans PI. Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J. 1993;106:392–3.

    CAS  PubMed  Google Scholar 

  65. Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol. 1993;28:490–2.

    CAS  PubMed  Google Scholar 

  66. Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed. 2006;5:90–2.

    PubMed  Google Scholar 

  67. Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35:447–50.

    CAS  PubMed  Google Scholar 

  68. Eriksen JG, Christiansen JJ, Asmussen I. Postulosis palmoplantaris caused by angiotensin-converting enzyme inhibitors. Ugeskr Laeger. 1995;157:3335–6.

    CAS  PubMed  Google Scholar 

  69. Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am J Ther. 2010;17:92–5.

    PubMed  Google Scholar 

  70. Ikai K. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol. 1995;32:819.

    CAS  PubMed  Google Scholar 

  71. Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J. 2006;12:1.

    PubMed  Google Scholar 

  72. Ghersetich I, Rindi L, Teofoli P, Tsampau D, Palleschi GM, Lotti T. Pityriasis rosea-like skin eruptions caused by captopril. G Ital Dermatol Venereol. 1990;125:457–9.

    CAS  PubMed  Google Scholar 

  73. Wilkin JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch Dermatol. 1982;118:186–7.

    CAS  PubMed  Google Scholar 

  74. Atzori L, Ferreli C, Pinna AL, Aste N. ‘Pityriasis rosea-like’ adverse reaction to lisinopril. J Eur Acad Dermatol Venereol. 2004;18:743–5.

    CAS  PubMed  Google Scholar 

  75. Puppin Jr D, Rybojad M, de la Chapelle C, Morel P. Kaposi’s sarcoma associated with captopril. Lancet. 1990;336:1251–2.

    PubMed  Google Scholar 

  76. Larbre JP, Nicolas JF, Collet P, Larbre B, Llorca G. Kaposi’s sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol. 1991;18:476–7.

    CAS  PubMed  Google Scholar 

  77. Bilen N, Bayramgurler D, Aydeniz B, Apaydin R, Ozkara SK. Possible causal role of lisinopril in a case of Kaposi’s sarcoma. Br J Dermatol. 2002;147:1042–4.

    CAS  PubMed  Google Scholar 

  78. Dervis E, Demirkesen C. Kaposi’s sarcoma in a patient with psoriasis vulgaris. Acta Dermatovenerol Alp Panonica Adriat. 2010;19:31–4.

    CAS  Google Scholar 

  79. Di Carlo A. Lisinopril and Kaposi’s sarcoma. Br J Dermatol. 2004;150:158–9.

    PubMed  Google Scholar 

  80. Vogt B, Frey FJ. Inhibition of angiogenesis in Kaposi’s sarcoma by captopril. Lancet. 1997;349:1148.

    CAS  PubMed  Google Scholar 

  81. Ratliff 3rd NB. Captopril induced lupus. J Rheumatol. 2002;29:1807–8.

    PubMed  Google Scholar 

  82. Patri P, Nigro A, Rebora A. Lupus erythematosus-like eruption from captopril. Acta Derm Venereol. 1985;65:447–8.

    CAS  PubMed  Google Scholar 

  83. Sieber C, Grimm E, Follath F. Captopril and systemic lupus erythematosus syndrome. BMJ. 1990;301:669.

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R. Captopril-induced lupus. Clin Exp Rheumatol. 1993;11:695.

    CAS  PubMed  Google Scholar 

  85. Carter JD, Valeriano-Marcet J, Kanik KS, Vasey FB. Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South Med J. 2001;94:1122–3.

    CAS  PubMed  Google Scholar 

  86. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45–9.

    CAS  PubMed  Google Scholar 

  87. Fernandez-Diaz ML, Herranz P, Suarez-Marrero MC, Borbujo J, Manzano R, Casado M. Subacute cutaneous lupus erythematosus associated with cilazapril. Lancet. 1995;345:398.

    CAS  PubMed  Google Scholar 

  88. Reidenberg MM, Case DB, Drayer DE, Reis S, Lorenzo B. Development of antinuclear antibody in patients treated with high doses of captopril. Arthritis Rheum. 1984;27:579–81.

    CAS  PubMed  Google Scholar 

  89. Pérez-Ferriols A, Martínez-Menchón T, Fortea JM. Follicular mucinosis secondary to captopril-induced photoallergy. Actas Dermosifiliogr. 2005;96:167–70.

    PubMed  Google Scholar 

  90. Rodríguez Granados MT, Abalde T, García Doval I, De la Torre C. Systemic photosensitivity to quinapril. J Eur Acad Dermatol Venereol. 2004;18:389–90.

    PubMed  Google Scholar 

  91. Wagner SN, Welke F, Goos M. Occupational UVA-induced allergic photodermatitis in a welder due to hydrochlorothiazide and ramipril. Contact Dermatitis. 2000;43:245–6.

    CAS  PubMed  Google Scholar 

  92. Smit AJ, Van der Laan S, De Monchy J, Kallenberg CG, Donker AJ. Cutaneous reactions to captopril. Predictive value of skin tests. Clin Allergy. 1984;14:413–9.

    CAS  PubMed  Google Scholar 

  93. Miralles R, Pedro-Botet J, Farre M, Rubies-Prat J. Captopril and vasculitis. Ann Intern Med. 1988;109:514.

    CAS  PubMed  Google Scholar 

  94. Laaban J, Marie JP, Wallach D, Blanchard D, Lafay M, Gruffaz F. Necrotising vasculitis associated with captopril therapy. Eur Heart J. 1987;8:319.

    Google Scholar 

  95. Guillevin L, Le Roux G, Breau JL. Leukocytoclasic vasculitis during treatment with low-dose captopril. Ann Med Interne (Paris). 1987;138:658–9.

    CAS  Google Scholar 

  96. Jensen ON, Ahlquist P. Schoenlein-Henoch purpura in a geriatric patient after captopril therapy. Ugeskr Laeger. 1996;158:4926–7.

    CAS  PubMed  Google Scholar 

  97. Carrington PR, Sanusi ID, Zahradka S, Winder PR. Enalapril-associated erythema and vasculitis. Cutis. 1993;51:121–3.

    CAS  PubMed  Google Scholar 

  98. Goncalves R, Cortez Pinto H, Serejo F, Ramalho F. Adult Schonlein-Henoch purpura after enalapril. J Intern Med. 1998;244:356–7.

    CAS  PubMed  Google Scholar 

  99. Moots RJ, Keeling PJ, Morgan SH. Adult Schonlein-Henoch purpura after enalapril. Lancet. 1992;340:304–5.

    CAS  PubMed  Google Scholar 

  100. Ayani I, Martinez MJ, Lekuona I, Manrique P. Enalapril-induced vasculitis. Med Clin (Barc). 1991;96:596.

    CAS  Google Scholar 

  101. Barlow RJ, Schulz EJ. Lisinopril-induced vasculitis. Clin Exp Dermatol. 1988;13:117–20.

    CAS  PubMed  Google Scholar 

  102. Disdier P, Harle JR, Verrot D, Jouglard J, Weiller PJ. Adult Schonlein-Henoch purpura after lisinopril. Lancet. 1992;340:985.

    CAS  PubMed  Google Scholar 

  103. Gupta S, Gandhi NM, Ferguson J. Cutaneous vasculitis secondary to ramipril. J Drugs Dermatol. 2004;3:81–2.

    CAS  PubMed  Google Scholar 

  104. Cnudde F, Leynadier F, Dry J. Cutaneous reaction to captopril: value of patch tests. Contact Dermatitis. 1990;23:375–6.

    CAS  PubMed  Google Scholar 

  105. Pfützner W, Rueff F, Przybilla B. Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril. Acta Derm Venereol. 2004;84:91–2.

    PubMed  Google Scholar 

  106. Martinez JC, Fuentes MJ, Armentia A, Vega JM, Fernandez A. Dermatitis to captopril. Allergol Immunopathol (Madr). 2001;29:279–80.

    CAS  Google Scholar 

  107. Touraud JP, Collet E, Louguet C, Sgro C, Dalac S, Dutronc Y, Lambert D. Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist. Ann Dermatol Venereol. 2002;129:1033–6.

    CAS  PubMed  Google Scholar 

  108. Solinger AM. Exfoliative dermatitis from captopril. Cutis. 1982;29:473–4.

    CAS  PubMed  Google Scholar 

  109. O’Neill PG, Rajan N, Charlat ML, Bolli R. Captopril-related exfoliative dermatitis. Tex Med. 1989;85:40–1.

    PubMed  Google Scholar 

  110. Goodfield MJ, Millard LG. Severe cutaneous reactions to captopril. Br Med J (Clin Res Ed). 1985;290:1111.

    CAS  Google Scholar 

  111. Pennell DJ, Nunan TO, O’Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet. 1984;1:463.

    CAS  PubMed  Google Scholar 

  112. Alkurtass DA, Al-Jazairi AS. Possible captopril-induced toxic epidermal necrolysis. Ann Pharmacother. 2003;37:380–3.

    PubMed  Google Scholar 

  113. Winfred RI, Nanda S, Horvath G, Elnicki M. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. South Med J. 1999;92:918–20.

    CAS  PubMed  Google Scholar 

  114. Oskay T, Ozcelik T, Kutluay L. Stevens-Johnson Syndrome associated with ramipril. Int J Dermatol. 2003;42:580–1.

    PubMed  Google Scholar 

  115. Chaabane A, Fadhl NB, Chadly Z, Fredj NB, Boughattas NA, Aouam K. Captopril-induced DRESS: first reported case confirmed by patch test. Dermatitis. 2013;24:255–7.

    PubMed  Google Scholar 

  116. Pileri A, Brunasso AM, Tilz H, Wolf P, Massone C. Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol. 2011;21:624–5.

    PubMed  Google Scholar 

  117. Motel PJ. Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol. 1990;23:124–5.

    CAS  PubMed  Google Scholar 

  118. Leaker B, Whitworth JA. Alopecia associated with captopril treatment. Aust N Z J Med. 1984;14:866.

    CAS  PubMed  Google Scholar 

  119. Ahmad S. Enalapril and reversible alopecia. Arch Intern Med. 1991;151:404.

    CAS  PubMed  Google Scholar 

  120. Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.

    Google Scholar 

  121. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol Rev. 2002;10:285–300.

    PubMed  Google Scholar 

  122. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull. 1987;34 Suppl 1:3–5.

    PubMed  Google Scholar 

  123. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004;15:28–46.

    PubMed  Google Scholar 

  124. Brown RS, Krakow AM, Douglas T. Choksi SK.“Scalded mouth syndrome” caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:665–7.

    CAS  PubMed  Google Scholar 

  125. Savino LB, Haushalter NM. Lisinopril-induced “scalded mouth syndrome”. Ann Pharmacother. 1992;26:1381–2.

    CAS  PubMed  Google Scholar 

  126. Triantos D, Kanakis P. Stomatodynia (burning mouth) as a complication of enalapril therapy. Oral Dis. 2004;10:244–5.

    CAS  PubMed  Google Scholar 

  127. Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis. 2010;16:769–73.

    CAS  PubMed  Google Scholar 

  128. Clayton R, Chaudhry S, Ali I, Cooper S, Hodgson T, Wojnarowska F. Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition? Clin Exp Dermatol. 2010;35:384–7. doi:10.1111/j.1365-2230.2009.03581.x.

    CAS  PubMed  Google Scholar 

  129. Schepis C, Lentini M, Siragusa M, Batolo D. ACE-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and Lupus erythematosus tumidus. Dermatology. 2004;208:354–5.

    PubMed  Google Scholar 

  130. Borders JV. Captopril and onycholysis. Ann Intern Med. 1986;105:305–6.

    CAS  PubMed  Google Scholar 

  131. Brueggemeyer CD, Ramirez G. Onycholysis associated with captopril. Lancet. 1984;1:1352–3.

    CAS  PubMed  Google Scholar 

  132. Biasi D, Caramaschi P, Carletto A, Bambara LM. Scleroderma and eosinophilic fasciitis in patients taking fosinopril. J Rheumatol. 1997;24:1242.

    CAS  PubMed  Google Scholar 

  133. O’Neil MB, Balfe JW, Geary DF. Captopril related hyperpigmentation. Br Med J. 1987;295:333.

    Google Scholar 

  134. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25:72–8.

    CAS  PubMed  Google Scholar 

  135. Perrin C, Lacour JP, Castanet J, Michiels JF. Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol. 2001;23:295–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Esen Özkaya & Kurtuluş Didem Yazganoğlu

Authors
  1. Esen Özkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurtuluş Didem Yazganoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Özkaya, E., Yazganoğlu, K.D. (2014). Angiotensin-Converting Enzyme Inhibitors. In: Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-6536-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6536-1_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6535-4

  • Online ISBN: 978-1-4471-6536-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation